Author response for "Benefit:Risk Profile of Dapagliflozin 5 mg in the DEPICT ‐1 and ‐2 Trials in Individuals with Type 1 Diabetes and BMI ≥27 kg/m 2 "
Diabetes, Obesity and Metabolism(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Diabetes, Obesity and Metabolism(2020)